The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

NCT01250171 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

BIOLOGICAL: Secukinumab 10 mg/kg
BIOLOGICAL: Canakinumab 10 mg/kg
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals